title: Piroxicam immediate release formulations: A fasting randomized open-label crossover bioequivalence study in healthy volunteers.
abstract: Piroxicam is a NSAID with analgesic and antipyretic properties, used for the treatment of rheumatoid diseases. The aim of this study was to evaluate the bioequivalence of two brands of piroxicam capsules (20 mg) in 24 Egyptian volunteers. The in vivo study was established according to a single-center, randomized, single-dose, laboratory-blinded, 2-period, 2-sequence, crossover study with a washout period of 3 weeks. Under fasting conditions, 24 healthy male volunteers were randomly selected to receive a single oral dose of one capsule (20 mg) of either test or reference product. Plasma samples were obtained over a 144-hour interval and analyzed for piroxicam by HPLC with UV detection. The pharmacokinetic parameters Cmax , tmax , AUC0-t , AUC0-∞ , Vd /F, Cl/F, and t1/2 were determined from plasma concentration-time profiles. The 90% confidence intervals for the ratio of log transformed values of Cmax , AUC0-t , and AUC0-∞ of the two treatments were within the acceptable range (0.8-1.25) for bioequivalence. From PK perspectives, the two piroxicam formulations were considered bioequivalent, based on the rate and extent of absorption. No adverse events occurred or were reported after a single 20-mg piroxicam and both formulations were well-tolerated.
authors.affiliation: Department of Pharmaceutics, Faculty of Pharmacy, Damanhour University, Damanhour, Egypt.
authors.forename: Sally A
authors.initials: SA
authors.lastname: Helmy
authors.affiliation: Department of Pharmaceutics, Faculty of Pharmacy, Damanhour University, Damanhour, Egypt.
authors.forename: Heba M
authors.initials: HM
authors.lastname: El-Bedaiwy
mesh_terms: D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage / Q000009:adverse effects / Q000737:chemistry / Q000493:pharmacokinetics*; D019540:Area Under Curve; D002214:Capsules; D018592:Cross-Over Studies; D003692:Delayed-Action Preparations; D004339:Drug Compounding; D004534:Egypt; D005215:Fasting / Q000097:blood; D006207:Half-Life; D064368:Healthy Volunteers; D006801:Humans; D008297:Male; D008657:Metabolic Clearance Rate; D008954:Models, Biological; D010894:Piroxicam / Q000008:administration & dosage / Q000009:adverse effects / Q000737:chemistry / Q000493:pharmacokinetics*; D013810:Therapeutic Equivalency; D055815:Young Adult
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D002214:Capsules; D003692:Delayed-Action Preparations; D010894:Piroxicam
keywords: HPLC; bioequivalence; human plasma; pharmacokinetics; piroxicam